Anti-SARS-CoV Drug Discovery Products

Severe acute respiratory syndrome coronavirus (SARS-CoV, also named SARS-CoV-1), a coronavirus, first appeared in Asia in 2003. SARS-CoV caused symptoms ranging from mild illness to serious forms of pneumonia, and sometimes death. SARS is recognized as a global threat. A new coronavirus that was very similar to SARS, called SARS-CoV-2, emerged in China, in 2019, spreading to everywhere in the world. A known hypothesis is that the emergence of SARS-CoV is the cross-species jump of coronavirus from bats to humans.

Like other Coronaviruses, the genome of SARS-CoV is a +ssRNA that encodes four structural proteins (spike protein S, envelope protein E, membrane protein M, and nucleocapsid protein N) for viral assembly and sixteen nonstructural proteins for viral RNA transcription and nine accessory proteins. The S protein contains two subunits, S1 and S2, and is responsible for host range and tissue tropism. The RBD of S1 protein binds to its cellular receptor ACE2, causing the attachment and entry of the virus into the host cell. At Creative Biolabs, we provide various anti-SARS-CoV antibodies that recognize S, M, E, N, and nonstructural proteins.